Your event should be here ! To publish, manage, promote... To learn or to be formed ... Online registrations

Site language : English - Français
Ref : 29052
Event :505(b)(2) NDAs

Date :Wednesday February 27th, 2019

Location :Palo Alto
2479 East Bayshore Road,
Suite 200
94303 Palo Alto, United States

Type :Conference & Seminar - International audience

Accreditation :--


 

Further information

Editorial

In this webinar attendees will learn which products qualify for submissions under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (FD & C) and the requirements for studies, reference information, and marketing requirements to take advantage of this great sponsorship opportunity.

Objectives

NDAs submitted under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (FD & C) are a those for which the product is not a generic nor a traditional brand. It allow sponsors to reference data that was not generated by them. This type of submission can shave years off of the development process and save millons of dollars. Attend this webinar to learn which products qualify for submissions under 505(b)(2), data that may be referenced, content requirements, and regulatory benefits.

Program

Areas Covered in the Webinar:

  • What is a 505(b)(2) NDA
  • What products qualify for submission under 505(b)(2)
  • Examples of data and information that may be referenced
  • Requirements for studies to be conducted
  • Submission content requirements
  • Limitations to and benefits of a 505(b)(2)
 

Speakers

Peggy Berry

Peggy Berry
Founder, Synergy Consulting LLC

Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting, she was Vice President of Regulatory Affairs at Insmed where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. She also worked as Vice President of Regulatory Affairs and Quality at Amarin and held a variety of senior level positions at Dyax, MGI Pharma, AstraZeneca and Dey Pharma. She has also held Regulatory Affairs roles within two clinical contract research organizations and has worked in review divisions at the FDA. In addition, Ms. Berry is active in the Regulatory Affairs Professionals Society. She is an editor-in-chief of Fundamentals of US Regulatory Affairs, 6th edition (RAPS, MD 2010). Editor of “Choosing the Right Regulatory Career” (RAPS, MD 2010) and author of “Communication & Negotiation” (RAPS, MD 2011).

Follow us :
 
 

Location

Map and directions
Conference address :
Palo Alto
2479 East Bayshore Road,
Suite 200
94303 Palo Alto
United States
tel : +1-888-717-2436
Map and directions

Further information

To access the information you need to be connected. Creating an account is easy and free!

Log to your account
Register on Doctorama

Details

505(b)(2) NDAs Hospital - Management
505(b)(2) nda, 505(b)(2) new drug application, fda 505 (b)(2) nda, 505(b)(2) product qualification, 505(b)(2) submission, 505(b)(2) limitations, 505(b)(2) training, 505(b)(2) webinar
Professionals, Manufacturing Supply Chain Technical Operations Quality Control Quality Assurance Regulatory Affairs
10 -- --
English

Other

For more information on 505(b)(2) NDAs, plsase contactr ComplianceOnline

To display announcer website, obtain a letter of invitation, you must be logged

Log to my account
Register on Doctorama


Recommend this event